×
About 860 results

ALLMedicine™ Gastric Tumors Center

Research & Reviews  296 results

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT03008278

Aug 2nd, 2022 - PRIMARY OBJECTIVES: I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of olaparib plus ramucirumab as measured by the obj...

Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
https://clinicaltrials.gov/ct2/show/NCT03027427

Jul 20th, 2022 - Background: Greater than 90% of gastric tumors are of epithelial origin and are classified as adenocarcinomas; the remainders include GIST, carcinoid and lymphoma Gastric adenocarcinoma is rare in the United States (incidence 7.4 per 100,000) Mort...

Gastrointestinal stromal tumors caused by novel germline variants in SDHB and KIT: a re...
https://doi.org/10.1007/s12328-022-01672-y
Clinical Journal of Gastroenterology; Rasmussen S, Stueck A et. al.

Jul 14th, 2022 - Gastrointestinal stromal tumors (GISTs) are usually caused by somatic mutations, but there are rare germline variants that predispose patients to the development of one or, more commonly, multiple GISTs. We present 2 cases of multifocal GISTs rela...

Clinical Study on the Evaluation of the Condition of Patients with Gastric Tumors and t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203228
Contrast Media & Molecular Imaging; Wang S, Hong Y et. al.

Jul 9th, 2022 - To explore the clinical value of the gastric ultrasonic filling method in evaluating the condition of patients with gastric tumors and guiding the selection of treatment methods, provide data support for clinical gastric filling ultrasonography in...

Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study
https://clinicaltrials.gov/ct2/show/NCT02491840

Jul 8th, 2022 - Some subtypes of gastric and cardia tumors such as adenocarcinoma or gastric linitis with disseminated cells respond poorly to the pre-operative chemotherapy, and some of them do not respond to chemotherapy usually performed. Doing chemotherapy in...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  19 results

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT03008278

Aug 2nd, 2022 - PRIMARY OBJECTIVES: I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of olaparib plus ramucirumab as measured by the obj...

Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
https://clinicaltrials.gov/ct2/show/NCT03027427

Jul 20th, 2022 - Background: Greater than 90% of gastric tumors are of epithelial origin and are classified as adenocarcinomas; the remainders include GIST, carcinoid and lymphoma Gastric adenocarcinoma is rare in the United States (incidence 7.4 per 100,000) Mort...

Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study
https://clinicaltrials.gov/ct2/show/NCT02491840

Jul 8th, 2022 - Some subtypes of gastric and cardia tumors such as adenocarcinoma or gastric linitis with disseminated cells respond poorly to the pre-operative chemotherapy, and some of them do not respond to chemotherapy usually performed. Doing chemotherapy in...

Clinical Study of 68Ga Labeled HER2 Affibody Analogues
https://clinicaltrials.gov/ct2/show/NCT05411432

Jun 9th, 2022 - 6 healthy volunteers with whole-body PET/CT scans at 0-1.0, 2.0, 3.0 and 4.0 hours after tracer injection (mean dose, 4.93 ± 0.10 mCi) will be performed. During the imaging period, 1 mL blood samples will be obtained specifically at 1, 3, 5, 10, 3...

Adenoma Detection Rate of 3D Colonoscopy
https://clinicaltrials.gov/ct2/show/NCT05153746

Dec 10th, 2021 - An accumulating body of evidence has shown that detection and resection of pre-cancerous adenoma by colonoscopy could effectively prevent colorectal cancer (CRC) and its related mortality. Among various colonoscopy quality indicators, such as ceca...

see more →

News  24 results

Pre-Op Chemosensitivity Tied to Post-Op Survival in Patients With Gastric Tumors
https://www.medscape.com/viewarticle/964279

Dec 8th, 2021 - NEW YORK (Reuters Health) - How long patients with resected gastric adenocarcinoma survive is tied to their preoperative sensitivity to chemotherapy, researchers report. "Interestingly, in patients with sensitive tumors, there was a significant su...

Trastuzumab Deruxtecan Shows Promise Beyond Breast and Gastric Tumors
https://www.onclive.com/view/trastuzumab-deruxtecan-shows-promise-beyond-breast-and-gastric-tumors

Oct 6th, 2021 - Bob T. Li, MD, MPH Fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201), a HER2-directed antibody¬—drug conjugate (ADC), demonstrated significant clinical activity in multiple non-breast, non-gastric cancer solid tumor types, according to findings ...

Potassium Acid Blocker No Better Than PPI for Artificial Gastric Ulcers
https://www.medpagetoday.com/gastroenterology/generalgastroenterology/92785

May 25th, 2021 - Vonoprazan, a potassium-competitive acid blocker, was not superior to the proton pump inhibitor (PPI) lansoprazole (Prevacid) for healing artificial gastric ulcers among patients with gastric tumors, Japanese researchers found in a randomized, ope...

Genetic Risk, Screening, and Diagnosis for Gastric Cancer
https://www.onclive.com/view/genetic-risk-screening-and-diagnosis-for-gastric-cancer

Apr 2nd, 2021 - Transcript:Johanna C. Bendell, MD: David, thinking about the family members, do you screen? Do you look at genetic risk factors for patients? David H. Ilson, MD, PhD: Just 1 other point about the global incidence is that there’s a shift globall...

Emerging Nivolumab Strategies in Gastric/GEJ Cancers
https://www.onclive.com/view/emerging-nivolumab-strategies-in-gastric-gej-cancers

Apr 2nd, 2021 - Transcript: Yelena Y. Janjigian, MD: We know the majority of patients will not benefit from anti—PD-1 therapy alone. The gastric tumors, although they are immunogenic and immune visible, are not as visible as some of the other immunogenic tumo...

see more →